Novocure
Yahoo Finance • last month
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results... Full story
Yahoo Finance • 5 months ago
Novocure to Report Second Quarter 2024 Financial Results
ROOT, Switzerland, July 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure manag... Full story
Yahoo Finance • 6 months ago
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with supportive care alone Patients treated with... Full story
Yahoo Finance • 6 months ago
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM Topline data to be presented Saturday, June 1, 2024 at the 2024 American Society of Clin... Full story
Yahoo Finance • 11 months ago
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
ROOT, Switzerland, January 04, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership a... Full story
Yahoo Finance • 11 months ago
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
ROOT, Switzerland, December 27, 2023--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive... Full story
Yahoo Finance • last year
11 Best Undervalued UK Stocks To Buy Now
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest eco... Full story
Yahoo Finance • last year
Novocure Reports Third Quarter 2023 Financial Results
Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 ROOT, Switzerland, October 26, 2023--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended Sep... Full story
Yahoo Finance • last year
NovoCure (NASDAQ:NVCR investor three-year losses grow to 90% as the stock sheds US$229m this past week
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of NovoCure Limited (NASDAQ:NVCR) investors who have... Full story
Yahoo Finance • last year
Lifshitz Law PLLC Announces Investigations of Peloton Interactive, Inc. (NASDAQ: PTON), DZS Inc. (NASDAQ: DZSI), TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), and NovoCure Ltd. (NASDAQ: NVCR)
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. (NASDAQ: PTON) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations... Full story
Yahoo Finance • last year
Novocure Plummets 34% After Its Cancer Treatment Fails In Ovarian Cancer
Novocure said Monday its cancer treatment failed to make a difference for ovarian cancer patients, and NVCR stock plummeted. Continue reading... Full story
Yahoo Finance • last year
Could NovoCure Stock Help You Become a Millionaire?
One mid-cap stock that could have significant upside is healthcare company NovoCure (NASDAQ: NVCR), which makes tumor treating fields (TTF) devices. There are some exciting ongoing studies in the company's pipeline that could make it a hot... Full story
Yahoo Finance • last year
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story
Yahoo Finance • last year
DEADLINE ALERT for NVCR, TIGR, GDS, AROW, IBRX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
BENSALEM, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story
Yahoo Finance • last year
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws... Full story
Yahoo Finance • last year
FRIDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that NovoCure Limited Investors with Substantial Losses Have Opportunity to Lead Case – NVCR
SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023, all dates inclusive (the “Class... Full story
Yahoo Finance • last year
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased bet... Full story
Yahoo Finance • last year
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
LOS ANGELES, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased... Full story
Yahoo Finance • last year
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story
Yahoo Finance • last year
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure”... Full story
